EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection

Catalin Prodan-Barbulescu iD, Luca Castiglione, Sonia Roxana Burtic, Marius Murariu iD, Shruta Reddy, Ovidiu Rosca iD, Felix Bratosin iD, Camelia Melania Fizedean iD, Pavel Krupyshev, Ileana Enatescu

Toxins · 2024

DOI: 10.3390/toxins16010059 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Toxins, 2024. Verfasst von Catalin Prodan-Barbulescu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Hyperhidrosis, Botulinum Toxins, Type A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Facial hyperhidrosis is a debilitating condition that can severely impact the quality of life. This study aimed to assess the long-term utility of Botulinum toxin type A therapy (BTA) for facial hyperhidrosis and its impact on quality of life over a one-year period. Conducted at the Pius Brinzeu Clinical Emergency Hospital in Timisoara, Romania, this longitudinal observational study involved 77 adult patients with primary facial hyperhidrosis. Participants received two sessions of Botulinum toxin injections (50 U IncoBTX-A each) and were evaluated at baseline, 6 months, and 12 months using the Hyperhidrosis Disease Severity Scale (HDSS), WHOQOL-BREF, Dermatology Life Quality Index (DLQI), and a bespoke survey. The study demonstrated significant reductions in HDSS scores from 3.6 ± 0.5 to 1.2 ± 0.8 post-treatment, sustained at 1.3 ± 0.6 at 12 months (p-value < 0.001). DLQI scores markedly decreased from 24.8 ± 4.2 to 6.2 ± 2.1 post-treatment, stabilizing at 6.5 ± 2.5 at 12 months (p-value < 0.001). Sweat production significantly dropped from 0.75 g ± 0.15 to 0.18 g ± 0.07 per 15 min (p-value < 0.001). WHOQOL-BREF scores improved notably in the mental domain from 66.7 ± 6.1 to 70.8 ± 5.2 at 12 months (p-value < 0.001), with physical and social domains also showing significant improvements. Correlation analysis revealed strong negative correlations between DLQI total score and HDSS (rho = −0.72, p-value < 0.001) and sweat production (rho = −0.68, p-value < 0.001). Regression analysis indicated significant predictors for DLQI total score, including HDSS (B Coefficient = −3.8, p-value < 0.001) and sweat production (B Coefficient = −2.2, p-value < 0.001). BTA therapy significantly improved the quality of life in facial hyperhidrosis patients, with lasting effects on symptom severity, sweat production, and quality of life domains. The correlation and regression analyses further substantiated the treatment’s impact on both physical and psychological aspects. These findings advocate Botulinum toxin as a viable long-term treatment for facial hyperhidrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperhidrosisBotulinum Toxins, Type AAdultHumansTreatment OutcomeQuality of LifeInjections, Intradermal

Stichwörter der Autor:innen

botoxhyperhidrosislongitudinal studiesquality of life

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • IInd Surgery Clinic, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Department I-Discipline of Anatomy and Embryology, Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Department of General Surgery, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Research Center for Medical Communication, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Department of General Medicine, SVS Medical College, Yenugonda, Mahbubnagar 509001, Telangana, India.

ORCID-Profile: Catalin Prodan-Barbulescu, Marius Murariu, Ovidiu Rosca, Felix Bratosin, Camelia Melania Fizedean

Zitieren

APA

Prodan-Barbulescu, C., Castiglione, L., Burtic, S. R., Murariu, M., Reddy, S., Rosca, O., Bratosin, F., Melania Fizedean, C., Krupyshev, P., & Enatescu, I. (2024). Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection. Toxins. https://doi.org/10.3390/toxins16010059

Vancouver

Prodan-Barbulescu C, Castiglione L, Burtic SR, Murariu M, Reddy S, Rosca O, et al. Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection. Toxins. 2024. doi:10.3390/toxins16010059

BibTeX
@article{ProdanBarbulescu2024,
  author = {Prodan-Barbulescu, Catalin and Castiglione, Luca and Burtic, Sonia Roxana and Murariu, Marius and Reddy, Shruta and Rosca, Ovidiu and Bratosin, Felix and Melania Fizedean, Camelia and Krupyshev, Pavel and Enatescu, Ileana},
  title = {Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection},
  journal = {Toxins},
  year = {2024},
  doi = {10.3390/toxins16010059}
}
Kostenlos starten →